Edition:
United States

Cytosorbents Corp (CTSO.OQ)

CTSO.OQ on NASDAQ Stock Exchange Capital Market

10.10USD
23 May 2018
Change (% chg)

$-0.38 (-3.58%)
Prev Close
$10.48
Open
$10.35
Day's High
$10.55
Day's Low
$10.00
Volume
106,100
Avg. Vol
26,094
52-wk High
$10.85
52-wk Low
$3.35

Select another date:

Mon, May 14 2018

BRIEF-Cytosorb Adds Bilirubin And Myoglobin Reduction To Eu Approved Indications For Use

* CYTOSORB® ADDS BILIRUBIN AND MYOGLOBIN REDUCTION TO EUROPEAN UNION APPROVED INDICATIONS FOR USE

BRIEF-CytoSorbents Reports Qtrly Loss Per Share $0.10

* CYTOSORBENTS REPORTS STRONG FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Cytosorbents Enrolls First Patient Into Pivotal U.S. Refresh 2-AKI Trial

* CYTOSORBENTS ENROLLS FIRST PATIENT INTO PIVOTAL U.S. REFRESH 2-AKI TRIAL USING CYTOSORB® DURING COMPLEX CARDIAC SURGERY Source text for Eikon: Further company coverage:

BRIEF-Cytosorbents Refinances Existing Debt With New $15 Mln Debt Facility With Bridge Bank

* CYTOSORBENTS REFINANCES EXISTING DEBT WITH NEW $15 MILLION DEBT FACILITY WITH BRIDGE BANK

BRIEF-Cytosorbents Achieves Record Revenue And Product Sales Growth In 2017

* CYTOSORBENTS ACHIEVES RECORD REVENUE AND PRODUCT SALES GROWTH IN 2017

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA

BRIEF-Cytosorbents Sees Q4 2017 Revenue About $4.6 Million

* CYTOSORBENTS PRE-ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND ISSUES STOCKHOLDER LETTER

BRIEF-U.S. FDA Approves Cytosorbents' Refresh 2 IDE Application With Conditions

* CYTOSORBENTS ACHIEVES KEY MILESTONE WITH FDA APPROVAL OF THE U.S. REFRESH 2 PIVOTAL CARDIAC SURGERY TRIAL IDE APPLICATION

Select another date: